How I do it: workup of severe asthma

How I do it: workup of severe asthma

Dettagli Bibliografici
Autori principali:	Couillard, S, Jackson, DJ, Wechsler, ME, Pavord, ID
Natura:	Journal article
Lingua:	English
Pubblicazione:	Elsevier 2021

Documenti analoghi

Fluticasone furoate: CAPTAIN of fluticasones in type 2 inflammatory asthma
di: Couillard, S, et al.
Pubblicazione: (2022)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
di: Oliver, ME, et al.
Pubblicazione: (2021)

Biological therapies for asthma
di: Couillard Castonguay, S, et al.
Pubblicazione: (2021)

A proof-of-concept scale to predict asthma attacks: the OxfoRd Asthma attaCk risk ScaLE (ORACLE)
di: Couillard, S, et al.
Pubblicazione: (2021)

Asthma in pregnancy: An update
di: Couillard, S, et al.
Pubblicazione: (2020)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
di: Howell, I, et al.
Pubblicazione: (2024)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
di: Couillard, S, et al.
Pubblicazione: (2021)

The Lancet COPD Commission: broader questions remain
di: Petousi, N, et al.
Pubblicazione: (2023)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
di: Moran, AM, et al.
Pubblicazione: (2020)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
di: Moran, A, et al.
Pubblicazione: (2020)

Mepolizumab, quality of life, and severe eosinophilic asthma.
di: Pavord, I
Pubblicazione: (2017)

Multidimensional assessment of severe asthma: A systematic review and meta‐analysis
di: Clark, VL, et al.
Pubblicazione: (2017)

Post-operative fever in orthopaedic surgery: How effective is the ‘fever workup?’
di: Blair Ashley, et al.
Pubblicazione: (2017-08-01)

Commentary: Pre-aesthetic workup: Should it be a part of pre-refractive surgery workup?
di: Ritika Sachdev
Pubblicazione: (2021-01-01)

The upper and lower airway microbiome in severe asthma
di: Jabeen, M, et al.
Pubblicazione: (2022)

Emerging biologics in severe asthma
di: Pavord, I, et al.
Pubblicazione: (2016)

FeNO non-suppression identifies corticosteroid-resistant type-2 signaling in severe asthma
di: Couillard, S, et al.
Pubblicazione: (2021)

Anti-IL-4/IL-13 for the treatment of asthma: the story so far
di: Moran, A, et al.
Pubblicazione: (2020)

Radiologic workup of lung cancer
di: Al Ghanem Sara
Pubblicazione: (2008-10-01)

Mechanisms of FeNO non-suppression in severe asthma: analysis of sputum type 2 cytokines and chemokines
di: Couillard, S, et al.
Pubblicazione: (2020)

Inflammatory and clinical prognostic factors for asthma attacks: a patient-level meta-analysis of control arms of 22 randomised trials
di: Meulmeester, FL, et al.
Pubblicazione: (2025)

How We Use Reticulocyte Parameters in Workup and Management of Pediatric Hematologic Diseases
di: Emilia Parodi, et al.
Pubblicazione: (2020-12-01)

Resistant Hypertension Workup and Approach to Treatment
di: Anastasios Makris, et al.
Pubblicazione: (2011-01-01)

Tympanosclerosis Presenting as Mass: Workup and Differential
di: Jonnae Y. Barry, et al.
Pubblicazione: (2016-01-01)

Pertinent issues in pretransplant recipient workup
di: Pranjal Modi
Pubblicazione: (2007-01-01)

Patient-specific workup of adrenal incidentalomas
di: Romy R. de Haan, et al.
Pubblicazione: (2017-01-01)

Biomarkers for severe eosinophilic asthma.
di: Yancey, S, et al.
Pubblicazione: (2017)

Type 2 inflammation and biological therapies in asthma: targeted medicine taking flight
di: Howell, I, et al.
Pubblicazione: (2023)

PB1935: MANAGEMENT OF NON-SEVERE APLASTIC ANEMIA: LABORATORY WORKUP AND TREATMENT PATTERNS.
di: G. Cassanello, et al.
Pubblicazione: (2022-06-01)

Blood eosinophils, fractional exhaled nitric oxide, and the risk of asthma attacks in randomised controlled trials: protocol for a systemic review and control arm patient-level meta-analysis for clinical prediction modelling
di: Couillard, S, et al.
Pubblicazione: (2022)

Interleukin-5 inhibitors for severe asthma: Rationale and future outlook.
di: Shrimanker, R, et al.
Pubblicazione: (2017)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
di: Shrimanker, R, et al.
Pubblicazione: (2017)

Associations between blood eosinophils and decline in lung function among adults with and without asthma
di: Hancox, RJ, et al.
Pubblicazione: (2018)

Antibiotics for asthma attacks: masking uncertainty
di: Ramakrishnan, S, et al.
Pubblicazione: (2021)

Is the neutrophil the key effector cell in severe asthma?
di: Kamath, A, et al.
Pubblicazione: (2005)

IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma
di: Luo, J, et al.
Pubblicazione: (2024)

Predicting the benefits of type-2 targeted anti-inflammatory treatment with the prototype OxfoRd Asthma attaCk risk scaLE (ORACLE)
di: Couillard Castonguay, S, et al.
Pubblicazione: (2022)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
di: Couillard, S, et al.
Pubblicazione: (2021)

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma
di: Berair, R, et al.
Pubblicazione: (2013)

Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.
di: Berair, R, et al.
Pubblicazione: (2013)